L-DOPA-quinone inactivates tryptophan hydroxylase and converts the enzyme to a redox-cycling quinoprotein

Molecular Brain Research

Volumn 73, Issue 1-2, 1999, Pages 78-84

  Kuhn, Donald M ^a   Arthur Jr , Robert E ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

L DOPA; Quinone; Redox cycling; Serotonin neuron; Tryptophan hydroxylase

Indexed keywords

LEVODOPA; QUINONE DERIVATIVE; TRYPTOPHAN HYDROXYLASE;

ARTICLE; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME MODIFICATION; NERVE CELL DEGENERATION; NONHUMAN; OXIDATION REDUCTION REACTION; PARKINSON DISEASE; PRIORITY JOURNAL;

ANTIOXIDANTS; BENZOQUINONES; BLOTTING, WESTERN; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME ACTIVATION; LEVODOPA; MONOPHENOL MONOOXYGENASE; NITROBLUE TETRAZOLIUM; OXIDATION-REDUCTION; REDUCING AGENTS; STAINING AND LABELING; SULFHYDRYL COMPOUNDS; TRYPTOPHAN HYDROXYLASE;

LETHRINIDAE;

EID: 0032751608     PISSN: 0169328X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-328X(99)00238-7     Document Type: Article

References (59)

1. Acedia Y., Hashiguchi H., Todaka K., Kuwahara I., Mitsuyama Y. Dopaminergic transplants alter in vivo activity of tryptophan hydroxylase in the striatum in a rat model of Parkinson's Disease. Neurosci. Lett. 210:1996;75-78.
2. Alam Z.I., Daniel S.E., Lees A.J., Marsden D.C., Jenner P., Halliwell B. A generalized increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J. Neurochem. 69:1997;1326-1329.
3. Alexander T., Sortwell C.E., Roth C.D.R.H., Steece-Collier K. Comparison of neurotoxicity following repeated administration of L-dopa, D-dopa, and dopamine to embryonic mesencephalic dopamine neurons in cultures derived from Fisher 344 and Sprague-Dawley donors. Cell Trans. 6:1997;309-315.
4. Arai R., Karasawa N., Geffard M., Nagatsu T., Nagatsu I. Immunohistochemical evidence that central serotonin neurons produce dopamine from exogenous L-DOPA in the rat, with reference to the involvement of aromatic L-amino acid decarboxylase. Brain Res. 667:1994;295-299.
5. Baez S., Segura-Aguilar J., Widersten M., Johansson A.S., Mannervik B. Glutathione transferases catalyze the detoxification of oxidized metabolites (o-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes. Biochem. J. 324:1997;25-28.
6. Basma A.N., Morris E.J., Nicklas W.J., Geller H.M. L-DOPA cytotoxicity to PC12 cells in culture is via its autooxidation. J. Neurochem. 64:1995;825-832.
7. Ben-Shachar D., Zuk R., Glinka Y. Dopamine neurotoxicity: inhibition of mitochondrial respiration. J. Neurochem. 64:1995;718-723.
8. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
9. Cheng N., Maeda T., Kume T., Kaneko S., Kochiyama H., Akaike A., Goshima Y., Misu Y. Differential neurotoxicity induced by L-DOPA and dopamine in cultured striatal neurons. Brain Res. 743:1996;278-283.
10. Darmon M.C., Guibert B., Leviel V., Ehret M., Maitre M., Mallet J. Sequence of two mRNAs encoding active rat tryptophan hydroxylase. J. Neurochem. 51:1988;312-316.
11. Dean R.T., Gebicki J., Geiseg S., Grant A.J., Simpson J.A. Hypothesis: a damaging role in aging for reactive protein oxidation products? Mutat. Res. 275:1992;387-393.
12. D'Sa C., Arthur R.E. Jr., Kuhn D.M. Expression and deletion mutagenesis of tryptophan hydroxylase fusion proteins: Delineation of the enzyme catalytic core. J. Neurochem. 67:1996;917-926.
13. Ellman G.L. Tissue sulfhydryl groups. Arch. Biochem. Biophys. 82:1959;70-77.
14. Fahn S. Welcome news about levodopa, but uncertainty remains. Ann. Neurol. 43:1998;551-554.
15. Fahn S., Cohen G. The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it. Ann. Neurol. 32:1992;804-812.
16. Fu S., Fu M.X., Baynes J.W., Thorpe S.R., Dean R.T. Presence of dopa and amino acid hydroperoxides in proteins modified with advanced glycation end products (AGEs): amino acid oxidation products as a possible source of oxidative stress induced by AGE proteins. Biochem. J. 330:1998;233-239.
17. Gartside S.E., Cowen P.J., Sharp T. Evidence that the large neutral amino acid L-valine decreases electrically-evoked release of 5-HT in rat hippocampus in vivo. Psychopharmacology. 109:1992;251-253.
18. Gieseg S.P., Simpson J.A., Charlton T.S., Duncan M.W., Dean R.T. Protein-bound 3,4-dihydroxyphenylalanine is a major reductant formed during hydroxyl radical damage to proteins. Biochemistry. 32:1993;4780-4786.
19. Graham D.G. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol. Pharmacol. 14:1978;633-643.
20. Graham D.G., Tiffany S.M., Bell W.R. Jr., Gutknecht W.F. Autooxidation vs. covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine and related compounds toward C1300 neuroblastoma cells in vitro. Mol. Pharmacol. 146:1978;44-653.
21. Halliday G.M., Blumbergs P.C., Cotton R.G., Blessing W.W., Geffen L.B. Loss of brain serotonin- and substance P-containing neurons in Parkinsons Disease. Brain Res. 510:1990;104-107.
22. Halliday G.M., Li Y.W., Blumbergs P.C., Joh T.H., Cotton R.G.H., Howe P.R.C., Blessing W.W., Geffen L.B. Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's Disease. Ann. Neurol. 27:1990;373-385.
23. Halliwell B. Reactive oxygen species and the central nervous system. J. Neurochem. 59:1992;1609-1623.
24. Hastings T.G., Lewis D.A., Zigmond M.J. The role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc. Natl. Acad. Sci. USA. 93:1996;1956-1961.
25. Hastings T.G., Lewis D.A., Zigmond M.J. Reactive dopamine metabolites and neurotoxicity. Adv. Exp. Med. Biol. 387:1996;97-106.
26. 3H ]dopamine: impact of ascorbic acid and glutathione J. Neurochem. 63:1994;1126-1132.
27. Jequier E., Lovenberg W., Sjoerdsma A. Tryptophan hydroxylase inhibition: the mechanism by which p-chlorophenylalanine depletes rat brain serotonin. Mol. Pharmacol. 3:1967;274-278.
28. Johansen P.A., Wolf W.A., Kuhn D.M. Inhibition of tryptophan hydroxylase by benserazide and other catechols. Biochem. Pharmacol. 41:1991;625-628.
29. Jonsson G., Sachs C. Actions of 6-hydroxydopamine quinones on catecholamine neurons. J. Neurochem. 25:1975;509-516.
30. Kato T., Ito S., Fujita K. Tyrosinase-catalyzed binding of 3,4-dihydroxyphenylalanine with proteins through the sulfhydryl group. Biochim. Biophys. Acta. 881:1986;415-421.
31. Kuhn D.M., Arthur R.E. Jr. Dopamine inactivates tryptophan hydroxylase and forms a redox-cycling quinoprotein: possible endogenous toxin to serotonin neurons. J. Neurosci. 18:1998;7111-7117.
32. Kuhn D.M., Arthur R.E. Jr. Molecular mechanism of the inactivation of tryptophan hydroxylase by nitric oxide: attack on critical sulfhydryls that spare the enzyme iron center. J. Neurosci. 17:1997;7245-7251.
33. Kuhn D.M., Arthur R.E. Jr., States J.C. Phosphorylation and activation of brain tryptophan hydroxylase: identification of serine-58 as a substrate site for protein kinase A. J. Neurochem. 68:1997;2220-2223.
34. Kuhn D.M., Ruskin B., Lovenberg W. Tryptophan hydroxylase: the role of oxygen, iron and sulfhydryl groups as determinants of stability and catalytic activity. J. Biol. Chem. 255:1980;4137-4143.
35. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
36. Li H., Shen X.-M., Dryhurst G. Brain mitochondria catalyze the oxidation of 7-(2-aminoethyl)-3,4dihydro-5-hydroxy-2H-1,4-benzothiazine-3-carboxylic acid (DHBT-1) to intermediates that irreversibly inhibit complex I and scavenge glutathione: Potential relevance to the pathogenesis of Parkinson's Disease. J. Neurochem. 71:1998;2049-2062.
37. Linert W., Herlinger E., Jameson R.F., Kienzl E., Jellinger K., Youdim M.B.H. Dopamine, 6-hydroxydopamine, iron and dioxygen-their mutual interactions and possible implication in the development of Parkinson's disease. Biochim. Biophys. Acta. 1316:1996;160-168.
38. Maruyama W., Naoi M., Takahashi A., Watanabe H., Konagaya Y., Mokuno K., Hasegawa S., Nakahara D. The mechanism of perturbation of in monoamine metabolism by L-DOPA therapy: in vivo and in vitro studies. J. Neural Trans. 90:1992;183-197.
39. Melamed E., Zoldan J., Friedberg G., Ziv I., Weizmann A. Involvement of serotonin in clinical features of Parkinson's disease and complications of L-DOPA therapy. Adv. Neurol. 69:1996;545-550.
40. Morin B., Davies M.J., Dean R.T. The protein oxidation product of 3,4-dihydroxy-phenylalanine (DOPA) mediates oxidative DNA damage. Biochem. J. 330:1998;1059-1067.
41. Naoi M., Marayuma W., Takahashi T., Ota M., Parvez H. Inhibition of tryptophan hydroxylase by dopamine and the precursor amino acids. Biochem. Pharmacol. 48:1994;207-211.
42. Nappi A.J., Vass E., Prota G., Memoli S. The effects of hydroxyl radical attack on dopa, dopamine, 6-hydroxydopa and 6-hydroxydopamine. Pigment. Cell Res. 8:1995;283-293.
43. Newcomer T.A., Rosenberg P.A., Aizenman E. Iron-mediated oxidation of 3,4-dihydroxyphenylalanine to an excitotoxin. J. Neurochem. 64:1995;1742-1748.
44. Olanow C.W., Tatton W.G. Etiology and pathogenesis of Parkinson's Disease. Ann. Rev. Neurosci. 22:1999;123-144.
45. Pardo B., Mena M.A., Casarejos M.J., Paino C.L., De Yebenes J.G. Toxic effects of L-DOPA on mesencephalic cell cultures: protection with antioxidants. Brain Res. 682:1995;133-143.
46. Paul S.M. Serotonin and its effects on human behavior. J. Clin. Psychiatry. 51(Suppl):1990;1-70.
47. Paz M.A., Fluckiger R., Boak A., Kagan H.M., Gallop P.M. Specific detection of quinoproteins by redox-cycling staining. J. Biol. Chem. 266:1991;689-692.
48. Rabinovic A.D., Hastings T.G. Role of endogenous glutathione in the oxidation of dopamine. J. Neurochem. 71:1998;2071-2078.
49. Riddles P.W., Blakeley R.L., Zerner B. Reassessment of Ellman's reagent. Meth. Enzymol. 91:1983;49-60.
50. Rosengren E., Linder-Eliasson E., Carlsson A. Detection of 5-S-cysteinyl-dopamine in human brain. J. Neural Trans. 63:1985;247-253.
51. Rowe D.B., Le W., Smith R.G., Appel S.H. Antibodies from patients with Parkinson's Disease react with protein modified by dopamine oxidation. J. Neurosci. Res. 53:1998;551-558.
52. Simpson J.A., Geiseg S.P., Dean R.T. Free radical and enzymatic mechanisms for the generation of protein bound reducing moieties. Biochim. Biophys. Acta. 1156:1993;190-196.
53. Simpson J.A., Narita S., Geiseg S., Gebicki S., Dean R.T. Long-lived reactive species on free-radical-damaged proteins. Biochem. J. 282:1992;621-624.
54. Smythies J., Galzigna L. The oxidative metabolism of catecholamines in the brain: A review. Biochim. Biophys. Acta. 1380:1998;159-162.
55. Spencer J.P.E., Jenner P., Daniel S.E., Lees A.J., Marsden D.C., Halliwell B. Conjugates of catecholamines with cysteine and GSH in Parkinson's Disease: possible mechanisms of formation involving reactive oxygen species. J. Neurochem. 71:1998;2112-2122.
56. Stokes A.H., Brown B.G., Lee C.K., Doolittle D.J., Vrana K.E. Tyrosinase enhances the covalent modification of DNA by dopamine. Mol. Brain Res. 42:1996;167-170.
57. Tanaka H., Kannari K., Maeda T., Tomiyama M., Suda T., Matsunaga M. Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport. 10:1999;631-634.
58. Tison F., Mons N., Geffard M., Henry P. The metabolism of exogenous L-DOPA in the brain: an immunohistochemical study of its conversion to dopamine in non-catecholaminergic cells of the rat brain. J. Neural Trans. 3:1991;27-39.
59. P.M. Whitaker-Azmitia, S.J. Peroutka (Eds.), The neuropharmacology of serotonin Ann. N.Y. Acad. Sci., 600, 1990, pp. 1-718.